AXA/2025/FY/Earnings release

Document info
Document ID	chq99br5nr
Organization	AXA
Year	2025
Period	FY
Period label	FY25
Document category	Earnings release
Document name	AXA Full Year 2025 Earnings Press Release
Publication date	2026-02-26
Language	English
Pages	20
Source	original URL
Stored file	.pdf file
Transcript	wiki page
Data	data page

This article summarizes AXA's Earnings release published on 2026-02-26 (20 pages).

c. 1; p. 1 Earnings release date

• Earnings release date: February 26, 2026, 6:45am CET.

Full Year 2025 Earnings

c. 2; p. 1 Underlying EPS growth

• AXA reported record results with underlying EPS growth at the top end of the target range.

Key FY25 highlights

c. 3; p. 1 Financial Performance

• Gross written premiums & other revenues¹(footnote: Change in gross written premiums & other revenues, new business value ('NBV') and present value of expected premiums ('PVEP') is on a comparable basis (constant forex, scope and methodology), unless otherwise indicated. These and other terms, including but not limited to contractual service margin ('CSM') and new business contractual service margin ('NB CSM'), are defined in the glossary section of this press release.): EUR 116bn, up +6% vs. FY24
• Underlying earnings²(footnote: 'Underlying earnings', 'underlying earnings per share', 'underlying return on equity', 'combined ratio' and 'debt gearing' are APMs as defined in ESMA's guidelines and the AMF's related position statement issued in 2015. AXA provides a reconciliation of such APMs to the most closely related line item, subtotal, or total in the financial statements of the corresponding period (and/or their calculation methodology, as applicable) in its Activity Report as of December 31, 2025 ('AXA's 2025 Activity Report'), on the pages indicated under the heading 'USE OF NON -GAAP AND ALTERNATIVE PERFORMANCE MEASURES'. For further information on the above-mentioned and other non-GAAP financial measures used in this press relea se, see the Glossary in AXA's 2025 Activity Report. AXA's 2025 Activity Report is available on AXA's website (www.axa.com).): EUR 8.4bn, up 6% vs. FY24
• Underlying earnings excluding AXA IM: up 9% vs. FY24
• Underlying earnings per share²(footnote: 'Underlying earnings', 'underlying earnings per share', 'underlying return on equity', 'combined ratio' and 'debt gearing' are APMs as defined in ESMA's guidelines and the AMF's related position statement issued in 2015. AXA provides a reconciliation of such APMs to the most closely related line item, subtotal, or total in the financial statements of the corresponding period (and/or their calculation methodology, as applicable) in its Activity Report as of December 31, 2025 ('AXA's 2025 Activity Report'), on the pages indicated under the heading 'USE OF NON -GAAP AND ALTERNATIVE PERFORMANCE MEASURES'. For further information on the above-mentioned and other non-GAAP financial measures used in this press relea se, see the Glossary in AXA's 2025 Activity Report. AXA's 2025 Activity Report is available on AXA's website (www.axa.com).): EUR 3.86, up +8% vs. FY24
• Underlying earnings per share included a -2% headwind from foreign exchange movements
• Underlying earnings per share included a -1% headwind from temporary earnings dilution from the sale of AXA IM due to timing of anti-dilutive share buyback⁴(footnote: On July 1, 2025, AXA executed a share repurchase agreement with an investment services provider, whereby AXA carried out a program to buyback its own shares for a maximum amount of Euro 3.8 billion to offset the earnings dilution from the sale of AXA Investment Managers to BNP Paribas, as announced on August 1, 2024. The share buyback commenced on July 2, 2025, and ended on January 20, 2026, resulting in a temporary earnings dilution as of December 31, 2025.)

c. 4; p. 1 Solvency II Ratio

• Solvency II ratio⁵(footnote: The Solvency II ratio is estimated primarily using AXA's internal model calibrated based on an adverse 1/200 years shock. For further information on AXA's internal model and Solvency II disclosures, please refer to AXA Group's Solvency and Financial Condition Report (SFCR) as of December 31, 2024, available on AXA's website (www.axa.com). The Solvency II ratio as of December 31, 2025 is adjusted to give effect to the full up to Euro 1.25 billion annual share buyback program and proposed Euro 2.32 per share dividend announced today.): 224% at December 31, 2025, up +9 points vs. FY24
• Solvency II ratio: 215% on January 1, 2026, reflecting the end of the grandfathering period⁶(footnote: Capital instruments and subordinated debt subject to Solvency II transitional measures were grandfathered until January 1, 2026, at which point they ceased to qualify as capital under Solvency II, as disclosed in AXA's press release on its 9M25 Activity Indicators, published on www.axa.com.)

Capital Management

c. 5; p. 1 Shareholder Returns

• Dividend of EUR 2.32 per share, up +8% vs. FY24⁷(footnote: Subject to approval by the Shareholders' Annual General Meeting to be held on April 30, 2026.)
• Launch of an annual share buyback program⁸(footnote: As approved by AXA's Board of Directors on February 25, 2026, and expected to commence as soon as reasonably practicable, subject to market conditions.) of up to EUR 1.25 billion
• Completion of EUR 3.8 billion additional share buyback related to AXA IM disposal⁴(footnote: On July 1, 2025, AXA executed a share repurchase agreement with an investment services provider, whereby AXA carried out a program to buyback its own shares for a maximum amount of Euro 3.8 billion to offset the earnings dilution from the sale of AXA Investment Managers to BNP Paribas, as announced on August 1, 2024. The share buyback commenced on July 2, 2025, and ended on January 20, 2026, resulting in a temporary earnings dilution as of December 31, 2025.), executed between July 2, 2025, and January 20, 2026

Outlook

c. 6; p. 1 Outlook and strategic plan

• Underlying earnings per share growth for 2026 is expected to be at the upper end of the 6-8% plan target range⁹(footnote: Expected underlying earnings per share ('UEPS') growth for 2026 is a forward -looking statement to provide one-off guidance in the context of the last year of the Group's current strategic plan and is qualified by the cautionary statements in this press rel ease regarding forward-looking statements.).
• The expected impact of Solvency II revision is +17 points¹⁰(footnote: Estimated based on the Solvency Capital Requirement (SCR) and the amount of capital under Solvency II as of January 1, 2026, as if the Solvency II revision had come into force on the same date.).
• AXA will present its new strategic plan for 2027-2029 on September 21, 2026.

c. 7; p. 1 2025 performance and segment results

• In 2025, AXA delivered +9% earnings growth in its core businesses excluding AXA IM.
• The company used these results to enhance reserve prudence.
• The P&C franchise posted strong results, combining a healthy balance between price and volume with best-in-class margins, a lower expense ratio, and higher investment income.
• AXA XL Insurance increased earnings with stable underlying margins.
• Life & Health earnings rose by 7%.
  • Life business reflected early benefits of the strategy to rejuvenate the business.
  • Health grew by 17%, even after absorbing the adverse change on VAT treatment in Mexico.
• Investments in automation and Artificial Intelligence are driving efficiency gains.
• The Solvency II ratio is at a very strong level.
• These results demonstrate the earnings power of AXA's well-diversified franchise and reinforce confidence in its ability to generate sustainable, long-term value.
• Thomas Buberl, Chief Executive Officer of AXA, thanked colleagues, agents, partners, and customers for their commitment and trust.

FY25 key highlights

c. 8; p. 2

1 | Gross written premiums & other revenues by business line, FY24 vs FY25.

In EUR million	FY24	FY25	Change on a reported basis	Change at comparable basis
Gross written premiums & other revenues 1(footnote: Change in gross written premiums & other revenues, new business value ('NBV') and present value of expected premiums ('PVEP') is on a comparable basis (constant forex, scope and methodology), unless otherwise indicated. These and other terms, including but not limited to contractual service margin ('CSM') and new business contractual service margin ('NB CSM'), are defined in the glossary section of this press release.)	110,316	115,524	+5%	+6%
o/w Property & Casualty	56,514	58,038	+3%	+5%
o/w Life & Health	51,983	56,512	+9%	+8%
o/w Asset Management	1,701	875	n.m.	n.m.

2 | Underlying earnings and net income, FY24 vs FY25.

	FY24	FY25	Change on a reported basis	Change at constant Forex
Underlying earnings 2(footnote: 'Underlying earnings', 'underlying earnings per share', 'underlying return on equity', 'combined ratio' and 'debt gearing' are APMs as defined in ESMA's guidelines and the AMF's related position statement issued in 2015. AXA provides a reconciliation of such APMs to the most closely related line item, subtotal, or total in the financial statements of the corresponding period (and/or their calculation methodology, as applicable) in its Activity Report as of December 31, 2025 ('AXA's 2025 Activity Report'), on the pages indicated under the heading 'USE OF NON -GAAP AND ALTERNATIVE PERFORMANCE MEASURES'. For further information on the above-mentioned and other non-GAAP financial measures used in this press relea se, see the Glossary in AXA's 2025 Activity Report. AXA's 2025 Activity Report is available on AXA's website (www.axa.com).)	8,078	8,368	+4%	+6%
Net income	7,886	9,797	+24%	+26%

3 | Solvency II ratio (%). FY24 vs FY25.

	FY24	FY25	Change on a reported basis
Solvency II ratio (%) 5(footnote: The Solvency II ratio is estimated primarily using AXA's internal model calibrated based on an adverse 1/200 years shock. For further information on AXA's internal model and Solvency II disclosures, please refer to AXA Group's Solvency and Financial Condition Report (SFCR) as of December 31, 2024, available on AXA's website (www.axa.com). The Solvency II ratio as of December 31, 2025 is adjusted to give effect to the full up to Euro 1.25 billion annual share buyback program and proposed Euro 2.32 per share dividend announced today.)	216%	224%	+9 pts	—

Activity indicators

c. 9; p. 2 Gross written premiums and other revenues

• Total gross written premiums and other revenues¹(footnote: Change in gross written premiums & other revenues, new business value ('NBV') and present value of expected premiums ('PVEP') is on a comparable basis (constant forex, scope and methodology), unless otherwise indicated. These and other terms, including but not limited to contractual service margin ('CSM') and new business contractual service margin ('NB CSM'), are defined in the glossary section of this press release.) were up 6%.
• Property & Casualty: +5%.
  • Commercial lines¹¹(footnote: 'Commercial lines' refers to P&C Commercial lines excluding AXA XL Reinsurance.): +4%, driven by higher volumes (notably at AXA XL Insurance) and favorable price effects¹²(footnote: Price effects are calculated as a percentage of total gross written premiums of the prior year.) across all geographies.
  • Personal lines: +7%, driven by favorable price effects and strong growth in net new contracts in France, Europe, Asia & EME-LATAM.
  • AXA XL Reinsurance: +8%, supported by alternative capital.
• Life & Health: +8%.
  • Life premiums: +9%.
    • Protection: +11% from strong sales in Hong Kong, Switzerland, and Japan.
    • Unit-Linked: +13% from higher volumes across all geographies.
    • G/A¹³(footnote: General account.): +4% from continued momentum in Italy and France.
  • Health premiums: +5%, driven by price effects in all geographies.

c. 10; p. 2 Underlying earnings

• Underlying earnings²(footnote: 'Underlying earnings', 'underlying earnings per share', 'underlying return on equity', 'combined ratio' and 'debt gearing' are APMs as defined in ESMA's guidelines and the AMF's related position statement issued in 2015. AXA provides a reconciliation of such APMs to the most closely related line item, subtotal, or total in the financial statements of the corresponding period (and/or their calculation methodology, as applicable) in its Activity Report as of December 31, 2025 ('AXA's 2025 Activity Report'), on the pages indicated under the heading 'USE OF NON -GAAP AND ALTERNATIVE PERFORMANCE MEASURES'. For further information on the above-mentioned and other non-GAAP financial measures used in this press relea se, see the Glossary in AXA's 2025 Activity Report. AXA's 2025 Activity Report is available on AXA's website (www.axa.com).) increased by 6% to EUR 8.4bn, or +9% excluding AXA IM³(footnote: AXA completed the disposal of AXA IM to BNP Paribas on July 1, 2025. All figures excluding AXA IM are given at constant foreign exchange rates.).
  • Property & Casualty: +9%, driven by higher volumes, underwriting margin expansion, and increased financial result from higher investment income.
  • Life & Health: +7%, from improved short-term technical results in Health & Protection and higher earnings in long-term business, including early benefits from strategy to rejuvenate the business.
  • Holdings¹⁴(footnote: Including banking activities.) underlying earnings remained stable at EUR -1.2bn.
  • Asset Management underlying earnings decreased by EUR 0.2bn due to the disposal of AXA IM on July 1, 2025.
• Underlying earnings per share²(footnote: 'Underlying earnings', 'underlying earnings per share', 'underlying return on equity', 'combined ratio' and 'debt gearing' are APMs as defined in ESMA's guidelines and the AMF's related position statement issued in 2015. AXA provides a reconciliation of such APMs to the most closely related line item, subtotal, or total in the financial statements of the corresponding period (and/or their calculation methodology, as applicable) in its Activity Report as of December 31, 2025 ('AXA's 2025 Activity Report'), on the pages indicated under the heading 'USE OF NON -GAAP AND ALTERNATIVE PERFORMANCE MEASURES'. For further information on the above-mentioned and other non-GAAP financial measures used in this press relea se, see the Glossary in AXA's 2025 Activity Report. AXA's 2025 Activity Report is available on AXA's website (www.axa.com).) increased by 8% to EUR 3.86.
  • This was mainly driven by the increase in underlying earnings (+6%) and a decrease in interest expense on undated and deeply-subordinated debt.
  • Also driven by the impact of share buybacks (+3%), including the annual share buyback program and the anti-dilutive share buyback associated with the sale of AXA IM.
  • Partially offset by the unfavorable impact of foreign exchange rate movements, notably the depreciation of the U.S. dollar against the Euro (-2%).
• The sale of AXA IM resulted in a temporary dilution of underlying earnings per share due to the timing of the associated share buyback (-1%).

c. 11; p. 2 Net income

• Net income increased by 26% to EUR 9.8bn.
• This reflects the increase in underlying earnings and significantly positive exceptional items, notably the gain from the sale of AXA IM.

Balance sheet

c. 12; p. 3 Shareholders' equity and CSM

• Shareholders' equity was EUR 47.2bn as of December 31, 2025, down EUR 2.8bn vs. December 31, 2024.
• The decrease in shareholders' equity was due to: net income (EUR +9.8bn) and net OCI (EUR +1.3bn) being offset by FY24 dividend paid (EUR -4.6bn), share buybacks (EUR -4.7bn) including a EUR 3.5bn anti-dilutive buyback for AXA IM sale, and unfavorable foreign exchange impact (EUR -3.5bn) mainly from USD depreciation.
• CSM¹(footnote: Change in gross written premiums & other revenues, new business value ('NBV') and present value of expected premiums ('PVEP') is on a comparable basis (constant forex, scope and methodology), unless otherwise indicated. These and other terms, including but not limited to contractual service margin ('CSM') and new business contractual service margin ('NB CSM'), are defined in the glossary section of this press release.)¹⁵(footnote: Including P&C. Please see Appendices of the FY25 earnings presentation available at www.axa.com for indicative sensitivities impacting CSM. These sensitivities, together with any other sensitivities contained in the Appendices, are based on management's current assessment in connection with the full -year 2025 annual results. These sensitivities are expressly qualified by the cautionary statements in the presentation concerning forward looking statements and have not been audited or subject to a limited review by AXA's statutory auditors.) was EUR 33.3bn at December 31, 2025, down EUR 0.6bn vs. December 31, 2024.
• CSM normalized growth was +2%, with new business contribution (EUR +2.2bn) and underlying return on in-force (EUR +1.3bn) offsetting CSM release (EUR -3.0bn).
• Market conditions had a favorable impact of EUR +0.6bn, driven by tightening government spreads and positive equity market performance.
• This was offset by unfavorable foreign exchange impacts (EUR -1.5bn), mainly from JPY and HKD depreciation, and a negative operating variance (EUR -0.3bn) due to better margins and net flows being offset by reduced duration of Group Life business in Switzerland.

c. 13; p. 3 Solvency II ratio

• Solvency II ratio⁵(footnote: The Solvency II ratio is estimated primarily using AXA's internal model calibrated based on an adverse 1/200 years shock. For further information on AXA's internal model and Solvency II disclosures, please refer to AXA Group's Solvency and Financial Condition Report (SFCR) as of December 31, 2024, available on AXA's website (www.axa.com). The Solvency II ratio as of December 31, 2025 is adjusted to give effect to the full up to Euro 1.25 billion annual share buyback program and proposed Euro 2.32 per share dividend announced today.) was 224% as of December 31, 2025, up +9 points vs. December 31, 2024.
• Drivers of Solvency II ratio change: strong operating return (+28 points) net of dividend provision and annual share buyback (-24 points), positive impact from net subordinated debt issuance (+6 points), and favorable financial markets (+4 points).
• These positive impacts were partly offset by the net impact of acquisitions (Nobis and Prima) and disposal of AXA IM, including the associated EUR 3.8bn share buyback (-5 points).
• As of January 1, 2026, the Solvency II ratio decreased by -10 points to 215% due to capital instruments and subordinated debt subject to Solvency II transitional measures no longer qualifying as eligible own funds.
• The Group estimates the Solvency II revision, effective Q1 2027, would increase the current Solvency II ratio¹⁰(footnote: Estimated based on the Solvency Capital Requirement (SCR) and the amount of capital under Solvency II as of January 1, 2026, as if the Solvency II revision had come into force on the same date.) by +17 points.

c. 14; p. 3 Financial metrics

• Underlying return on equity²(footnote: 'Underlying earnings', 'underlying earnings per share', 'underlying return on equity', 'combined ratio' and 'debt gearing' are APMs as defined in ESMA's guidelines and the AMF's related position statement issued in 2015. AXA provides a reconciliation of such APMs to the most closely related line item, subtotal, or total in the financial statements of the corresponding period (and/or their calculation methodology, as applicable) in its Activity Report as of December 31, 2025 ('AXA's 2025 Activity Report'), on the pages indicated under the heading 'USE OF NON -GAAP AND ALTERNATIVE PERFORMANCE MEASURES'. For further information on the above-mentioned and other non-GAAP financial measures used in this press relea se, see the Glossary in AXA's 2025 Activity Report. AXA's 2025 Activity Report is available on AXA's website (www.axa.com).) was 16.0% as of December 31, 2025, up 0.8 point vs. December 31, 2024, due to higher underlying earnings and lower shareholders' equity.
• Debt gearing²(footnote: 'Underlying earnings', 'underlying earnings per share', 'underlying return on equity', 'combined ratio' and 'debt gearing' are APMs as defined in ESMA's guidelines and the AMF's related position statement issued in 2015. AXA provides a reconciliation of such APMs to the most closely related line item, subtotal, or total in the financial statements of the corresponding period (and/or their calculation methodology, as applicable) in its Activity Report as of December 31, 2025 ('AXA's 2025 Activity Report'), on the pages indicated under the heading 'USE OF NON -GAAP AND ALTERNATIVE PERFORMANCE MEASURES'. For further information on the above-mentioned and other non-GAAP financial measures used in this press relea se, see the Glossary in AXA's 2025 Activity Report. AXA's 2025 Activity Report is available on AXA's website (www.axa.com).) was 22.3% as of December 31, 2025, up 1.7 points vs. December 31, 2024.
• Debt gearing increase was driven by lower shareholders' equity and CSM, and the issuance of Restricted Tier 1 and Tier 2 subordinated debt (EUR 3.5bn), partly offset by redemption of outstanding grandfathered Tier 1 debt (EUR -1.9bn).
• The Group's debt gearing was in line with its 19-23% plan guidance for 2024-2026.
• Cash at Holding¹⁶(footnote: Including cash and liquid invested assets at AXA SA Holding and other central holdings.) amounted to EUR 5.6bn as of December 31, 2025, up EUR 1.6bn vs. December 31, 2024.
• This increase reflected organic cash remittance from subsidiaries of EUR 7.5bn, up EUR 0.4bn vs. December 31, 2024.

Capital management and outlook

Capital management

c. 15; p. 4 Shareholder distributions

• A dividend of EUR 2.32 per share (+8% vs FY24) will be proposed at the Shareholders' Annual General Meeting on April 30, 2026⁷(footnote: Subject to approval by the Shareholders' Annual General Meeting to be held on April 30, 2026.).
• The dividend is expected to be paid on May 13, 2026, with an ex-dividend date on May 11, 2026.
• AXA's Board of Directors approved on February 25, 2026, the launch of an annual share buyback program for up to EUR 1.25bn.
• The share buyback program will be executed in accordance with the terms of the applicable Shareholders' Annual General Meeting authorization.
• AXA intends to cancel all shares repurchased under this program.
• The share buyback program is expected to commence as soon as reasonably practicable, subject to market conditions, and be completed by year-end.

Outlook

c. 16; p. 4 'Unlock the Future' plan targets and strategy

• AXA is confident in achieving its main financial targets for the 2024-2026 'Unlock the Future' plan.
• This confidence is based on profitable organic growth, scaling technical capabilities across businesses, and driving operational efficiency through reinforced cost management.

c. 17; p. 4 Business line outlook

• P&C Retail and SME & Mid-market: pricing remains favorable, and the Group expects to benefit from the earnthrough of higher pricing and underwriting actions.
• AXA XL: pricing conditions vary by line; the Group will continue effective cycle management and disciplined capital allocation, growing where returns exceed the cost of capital.
• The Group guidance for normalized natural catastrophe¹⁸(footnote: Natural catastrophe charges include natural catastrophe losses regardless of event size.) load remains at ca. 4.5 points of combined ratio for 2026.
• Life & Health: earnings growth is expected from the short-term business due to disciplined pricing and claims management.
• The strategy to rejuvenate sales in the long-term business and improved persistency should generate positive net flows, driving CSM growth over time.
• Holdings: results in 2026 are expected to remain similar to 2025.

c. 18; p. 4 Financial targets and capital management

• Management believes AXA is on track to deliver the main financial targets of the 'Unlock the Future' plan, assuming current operating conditions persist and following strong overall operating performance in 2025.
• Underlying earnings per share growth: at the upper end of the 6-8% CAGR target range for both the 2023-2026E plan period and for 2026⁹(footnote: Expected underlying earnings per share ('UEPS') growth for 2026 is a forward -looking statement to provide one-off guidance in the context of the last year of the Group's current strategic plan and is qualified by the cautionary statements in this press rel ease regarding forward-looking statements.).
• Underlying return on equity: between 14% and 16% between 2024 and 2026E.
• Cumulative organic cash upstream: in excess of Euro 21 billion for 2024-2026E.
• The Group is committed to its capital management policy¹⁹(footnote: Subject to annual Board and Shareholders' Annual General Meeting approvals and absent (1) for share buybacks, any significant earnings event (i.e., significant deviation in the Group's underlying earnings) and (2) for dividends, the occurrence of a signifi cant capital event (i.e., event that significantly deteriorates Group solvency). Board discretion includes taking into account AXA's earnings, financial condition, applicable c apital and solvency requirements, prevailing operating and financial market conditions and the general economic environment.), targeting a total payout ratio of 75%²⁰(footnote: Payout ratio is calculated based on underlying earnings per share.).
• This total payout ratio comprises a 60% dividend payout ratio and an additional 15% from annual share buybacks.
• The proposed dividend per share in a given year is expected to be at least equal to the dividend per share paid in the prior year.

Property & Casualty

c. 19; p. 5

4 | Property & Casualty gross written premiums and other revenues by business line, FY24 vs FY25.

In EUR billion	FY24	FY25	Change on a comparable basis	FY25 Price effect12(footnote: Price effects are calculated as a percentage of total gross written premiums of the prior year.) (in %)
Gross written premiums and other revenues	56.5	58.0	+5%	+2.9%
o/w Commercial lines11(footnote: 'Commercial lines' refers to P&C Commercial lines excluding AXA XL Reinsurance.)	34.9	35.8	+4%	+1.9%
o/w Personal lines	19.1	19.7	+7%	+5.2%
o/w AXA XL Reinsurance	2.5	2.6	+8%	+0.3%

5 | Property & Casualty: combined ratio and underlying earnings, FY24 vs FY25.

	FY24	FY25	Change at constant Forex
All-Year Combined ratio	91.0%	90.6%	-0.3 pt
Underlying earnings	5,510	5,872	+9%

c. 20; p. 5 Gross written premiums & other revenues

• Gross written premiums & other revenues were up 5% to EUR 58.0bn.
• Commercial lines grew by 4% to EUR 35.8bn, driven by:
  • AXA XL Insurance (+3%) from growth in lines with attractive margins, including Property and Casualty (from favorable price effects and higher volumes), partly offset by lower pricing and volumes in Financial lines.
  • Asia, Africa & EME-LATAM (+13%) mainly driven by Türkiye from higher average premiums, along with favorable volume and price effects in Mexico.
  • France (+6%) from favorable price effects in all lines of business and higher volumes.
• Personal lines grew by 7% to EUR 19.7bn, driven by:
  • Europe (+5%) from favorable price effects across geographies, except in UK & Ireland Motor, where pricing softened following strong repricing in 2024.
  • Asia, Africa & EME-LATAM (+14%) driven by Türkiye from higher average premiums and volumes.
  • France (+9%) with strong volume growth in all lines of business, from direct business and proprietary agent networks, combined with favorable price effects in Motor.
• AXA XL Reinsurance grew by 8% to EUR 2.6bn, driven by growth supported by alternative capital and favorable price effects in Casualty, partly offset by a softening in other lines.

c. 21; p. 5 Combined ratio

• The all-year combined ratio improved by 0.3 points to 90.6%, mainly driven by:
  • Lower undiscounted current year loss ratio excluding natural catastrophe (-0.3 points) from further margin expansion in Commercial lines (-0.5 points), driven by the SME & mid-market business (-0.9 points) in a favorable pricing environment, while margins at AXA XL Insurance were stable at attractive levels (+0.1 points).
  • Lower undiscounted current year loss ratio excluding natural catastrophe (-0.3 points) from further margin expansion in Personal lines (-0.4 points) in a conducive pricing environment.
  • Lower expense ratio (-0.3 points) primarily from lower non-commission expense ratio reflecting efficiency gains.
  • Lower natural catastrophe charges (-0.4 points to 3.4%) more than offset by lower prior years' reserve development (+0.7 points at -1.1%).

c. 22; p. 6 P&C underlying earnings

• P&C underlying earnings were up 9% to EUR 5.9bn driven by:
  • Increase in technical result (EUR +0.5bn) reflecting strong growth in volumes, combined with an improvement in technical margin.
  • Higher financial result (EUR +0.2bn) thanks to higher volumes and reinvestment yields on fixed income assets, more than offsetting the increase in the unwind of the discount of claims reserves.
  • Partly offset by higher income taxes (EUR -0.2bn) mainly due to higher pre-tax underlying earnings.

Life & Health

c. 23; p. 6

6 | Life & Health gross written premiums & other revenues, PVEP, NB CSM, NBV, NBV margin, and net flows, FY24 vs FY25.

In EUR billion	FY24	FY25	Change on a comparable basis
Gross written premiums & other revenues	52.0	56.5	+8%
o/w Life	34.5	37.5	+9%
o/w Health	17.5	19.0	+5%
PVEP1,21	50.9	49.4	-2%
NB CSM1,21	2.2	2.2	+3%
NBV (post-tax)1,21	2.3	2.2	0%
NBV margin1,21	4.4%	4.5%	+0.1 pt
Net flows21(footnote: Life & Health net flows, PVEP, CSM, NB CSM, NBV, and NBV margin include Health business predominantly written in Life entities.)	+1.5	+5.4	—

7 | Life & Health underlying earnings by business line, FY24 vs FY25.

	FY24	FY25	Change at constant forex
Underlying earnings	3,323	3,501	+7%
o/w Life	2,636	2,715	+4%
o/w Health	687	787	+17%

Gross written premiums & other revenues were up 8% to Euro 56.5 billion.

c. 24; p. 6 Life & Health gross written premiums

• Life GWP grew by 9% to EUR 37.5bn, mainly from:
  • Unit-Linked (+13%) driven by successful sales initiatives across all geographies.
  • G/A¹³(footnote: General account.) (+4%) notably in France (+4%) and from elevated sales of a capital-light product in Italy, partly offset by the non-repeat of elevated sales of a single premium whole-life product in Japan, and lower sales in Hong Kong.
  • Protection (11%), notably from a commercial campaign on a Protection with G/A product in Hong Kong and continued good sales of Protection with Unit-Linked product in Japan and Switzerland.
• Health GWP grew by 5% to EUR 19.0bn, driven by favorable price effects in both Group and Individual businesses across most geographies, partly offset by lower volumes.

c. 25; p. 6 Present value of expected premiums

• Present value of expected premiums (PVEP)^1,21 decreased by 2% to EUR 49.4bn driven by:
  • Life (+1%), from higher volumes in Hong Kong, France, and Switzerland, partly offset by the impact of higher interest rates on discounting of future premiums.
  • Health (-12%), mainly from the impact of higher interest rates on discounting of future premiums, and lower volumes in France following underwriting and pruning actions.

c. 26; p. 7 New business value

• NB CSM¹(footnote: Change in gross written premiums & other revenues, new business value ('NBV') and present value of expected premiums ('PVEP') is on a comparable basis (constant forex, scope and methodology), unless otherwise indicated. These and other terms, including but not limited to contractual service margin ('CSM') and new business contractual service margin ('NB CSM'), are defined in the glossary section of this press release.)²¹(footnote: Life & Health net flows, PVEP, CSM, NB CSM, NBV, and NBV margin include Health business predominantly written in Life entities.) increased by 3% to EUR 2.2bn driven by strong sales in Savings and Protection, partly offset by the impact of higher interest rates on discounting of future profits.
• NBV (post-tax)¹(footnote: Change in gross written premiums & other revenues, new business value ('NBV') and present value of expected premiums ('PVEP') is on a comparable basis (constant forex, scope and methodology), unless otherwise indicated. These and other terms, including but not limited to contractual service margin ('CSM') and new business contractual service margin ('NB CSM'), are defined in the glossary section of this press release.)²¹(footnote: Life & Health net flows, PVEP, CSM, NB CSM, NBV, and NBV margin include Health business predominantly written in Life entities.) was stable at EUR 2.2bn as growth in NB CSM was offset by the decrease in the contribution of short-term multinational business in France.
• NBV margin (post tax)¹(footnote: Change in gross written premiums & other revenues, new business value ('NBV') and present value of expected premiums ('PVEP') is on a comparable basis (constant forex, scope and methodology), unless otherwise indicated. These and other terms, including but not limited to contractual service margin ('CSM') and new business contractual service margin ('NB CSM'), are defined in the glossary section of this press release.)²¹(footnote: Life & Health net flows, PVEP, CSM, NB CSM, NBV, and NBV margin include Health business predominantly written in Life entities.) increased by 0.1 point to 4.5%.

c. 27; p. 7 Net flows

• Net flows²¹(footnote: Life & Health net flows, PVEP, CSM, NB CSM, NBV, and NBV margin include Health business predominantly written in Life entities.) were EUR +5.4bn compared to EUR +1.5bn in 2024, driven by:
  • Protection (EUR +4.9bn), mainly in Hong Kong, Japan, and France.
  • Health (EUR +2.7bn), mainly in Germany, Japan, and France.
  • Unit-Linked (EUR +1.5bn), primarily in France.
  • Partly offset by G/A Savings (EUR -3.7bn), as inflows in G/A capital-light (EUR +1.2bn) were more than offset by outflows in traditional G/A Savings (EUR -5.0bn).

c. 28; p. 7 Life & Health underlying earnings

• Life & Health underlying earnings increased by 7% to EUR 3.5bn, driven by:
  • Long-term technical result (EUR +0.2bn) driven by an increase in CSM release, following both growth in reserves and better margins in the long-term business.
  • Short-term technical result (EUR +0.1bn) driven by the expansion of technical margin reflecting pricing, underwriting and claims management actions to strengthen technical excellence across geographies, which more than offset the impact of a legislative change on the recoverability of value added tax in Mexico (EUR -0.1bn).
  • Lower income taxes (EUR +0.1bn) reflecting favorable tax effects mainly in Germany, France and Mexico.
  • Lower contribution from affiliates, notably ICBC-AXA and improved results at AXA MPS that resulted in an increase in earnings of minority shareholders.

Holdings

c. 29; p. 7 Holdings underlying earnings

• Holdings underlying earnings¹⁴(footnote: Including banking activities.) remained broadly stable at EUR -1.2bn.

Ratings and glossary

Ratings

c. 30; p. 8

8 | Insurer financial strength and credit ratings by agency, as of October 2025.

Agency	Date of last review	Insurer financial strength ratings AXA SA	Insurer financial strength ratings AXA's principal insurance subsidiaries	Insurer financial strength ratings Outlook	AXA's credit ratings 22(footnote: AXA maintains up-to-date ratings information on its website at: https://www.axa.com/en/investor/financial-strength-ratings.) Senior debt of the Company	AXA's credit ratings 22(footnote: AXA maintains up-to-date ratings information on its website at: https://www.axa.com/en/investor/financial-strength-ratings.) Short-term debt of the Company
S&P Global Ratings	October 3, 2025	A+	AA-	Positive	A+	A-1+
Moody's Investor Service	October 8, 2025	Aa2	Aa2	Stable	Aa3	P-1
AM Best	October 9, 2025	A+ Superior	—	Stable	aa Superior	—

(22) AXA maintains up-to-date ratings information on its website at: https://www.axa.com/en/investor/financial-strength-ratings.

Glossary

c. 31; p. 8 IFRS 17 metrics

• Capital-light G/A products: products with no guarantees, guarantees at maturity only, or guarantees equal to or lower than 0%.
• Contractual service margin ("CSM"): a component of the carrying amount of the asset or liability for a group of insurance contracts, representing unearned profit to be recognized as services are provided to policyholders.
• CSM release: the portion of CSM stock net of reinsurance at period end flowing through profit and loss, representing estimated profit earned by the insurer for providing insurance services during the reporting period.
• Economic variance: the variance of year-end CSM from changes in market conditions, net of the underlying return on in-force.
• Financial result: investment income on assets backing Building Block Approach (BBA) and Premium Allocation Approach (PAA) contracts, and assets backing shareholder's equity, net of insurance finance expenses (IFE) defined as the unwind of the present value of future cash flow.
• Gross written premiums and other revenues: insurance premiums collected during the period (including risk premiums, premiums from pure investment contracts with no discretionary participating features, fees and revenues, net of commissions paid on assumed reinsurance business).
• Other Revenues represent premiums and fees collected on activities other than insurance (i.e., banking, services, and asset management activities).
• New business contractual service margin ("NB CSM"): a component of the carrying amount of the asset or liability for newly issued insurance contracts during the period, representing unearned profit to be recognized as insurance contract services are provided.
• New business value ("NBV"): the value of newly issued contracts during the current year, consisting of the sum of:
  • the NB CSM
  • the present value of future profits of Short-Term Business newly issued contracts during the period, carried by Life entities, considering expected renewals
  • the present value of future profits of pure investment contracts accounted for under IFRS 9
  • net of the cost of reinsurance, taxes, and minority interests
• New business value margin ("NBV Margin"): the ratio of NBV (value of newly issued contracts during the current year) to PVEP.

c. 31; p. 9

• Operating variance: the variation of year-end CSM versus expected at opening due to:
  • differences between realized and expected operational assumptions
  • changes in assumptions such as mortality, longevity, lapses, and expenses
  • impact of model changes
• Operating variance is net of reinsurance.
• Present value of expected premiums ('PVEP'): the new business volume, equal to the present value at the time of issue of total premiums expected to be received over the policy term.
• PVEP is discounted at the reference interest rate and is Group share.
• Technical experience: consists of impacts on underlying earnings from:
  • the difference between expected and incurred cash-flows in the defined period
  • the risk adjustment release
  • changes in onerous contracts
  • other long-term elements, mainly non-attributable expenses
• Underlying return on in-force: the release of the time value of options & guarantees plus the unwind of CSM at the reference rate plus the underlying financial over-performance.

Scope and exchange rates

Scope

c. 32; p. 10 Scope of France segment

• France segment includes insurance activities, banking activities, and holding activities.

c. 33; p. 10 Scope of Europe segment

• Europe segment includes:
  • Switzerland (insurance activities).
  • Germany (insurance activities and holding).
  • Belgium and Luxembourg (insurance activities and holding).
  • United Kingdom and Ireland (insurance activities and holding).
  • Spain (insurance activities and holding).
  • Italy (insurance activities).
  • Prima (insurance activities)²³(footnote: AXA completed its acquisition of a majority stake in Prima in Italy on November 28, 2025.).
  • AXA Life Europe (insurance activities).
• AXA XL includes insurance and reinsurance activities and holding.

c. 34; p. 10 Scope of Asia, Africa & EME-LATAM segment

• Asia, Africa & EME-LATAM segment includes:
  • Asia:
    • Fully consolidated: Japan (insurance activities and holding), Hong Kong (insurance activities), Thailand P&C, Indonesia L&S (excluding bancassurance entity), China P&C, South Korea, and Asia Holdings.
    • Consolidated under equity method (contributing to NBV, PVEP, underlying earnings, and net income): China L&S, Thailand L&S, Philippines L&S and P&C, Indonesia L&S, and India (Life activities disposed on March 11, 2024, and holding) businesses.
  • Africa:
    • Fully consolidated: Egypt (insurance activities and holding), Morocco (insurance activities and holding), and Nigeria (insurance activities and holding).
  • EME-LATAM:
    • Fully consolidated: Mexico (insurance activities), Colombia (insurance activities), Brazil (insurance activities and holding), and Türkiye (insurance activities and holding).
    • Consolidated under equity method (contributing to net income only): Russia (Reso) (insurance activities).
  • AXA Mediterranean Holdings.

c. 35; p. 10 Scope of Transversal & Other segment

• Transversal & Other segment includes AXA Assistance, AXA Liabilities Managers, AXA SA (including Group's internal reinsurance activity), and other Central Holdings.

c. 36; p. 10 Scope of AXA Investment Managers segment

• AXA Investment Managers²⁴(footnote: Disposal to BNP Paribas completed on July 1, 2025.) segment includes:
  • Fully consolidated: AXA Investment Managers, Select (previously Architas), and Capza.
  • Consolidated under equity method: Asian joint ventures.

Exchange rates

c. 37; p. 10

9 | Exchange rates: end of period and average by currency, FY24 vs FY25.

For 1 Euro	End of Period Exchange rate FY24	End of Period Exchange rate FY25	Average Exchange rate FY24	Average Exchange rate FY25
USD	1.04	1.17	1.08	1.13
CHF	0.94	0.93	0.95	0.94
GBP	0.83	0.87	0.85	0.86
JPY	163	184	164	169
HKD	8.04	9.14	8.44	8.82

Notes

c. 38; p. 11 Notes

(1) Change in gross written premiums & other revenues, new business value ('NBV') and present value of expected premiums ('PVEP') is on a comparable basis (constant forex, scope and methodology), unless otherwise indicated. These and other terms, including but not limited to contractual service margin ('CSM') and new business contractual service margin ('NB CSM'), are defined in the glossary section of this press release.

(2) 'Underlying earnings', 'underlying earnings per share', 'underlying return on equity', 'combined ratio' and 'debt gearing' are APMs as defined in ESMA's guidelines and the AMF's related position statement issued in 2015. AXA provides a reconciliation of such APMs to the most closely related line item, subtotal, or total in the financial statements of the corresponding period (and/or their calculation methodology, as applicable) in its Activity Report as of December 31, 2025 ('AXA's 2025 Activity Report'), on the pages indicated under the heading 'USE OF NON -GAAP AND ALTERNATIVE PERFORMANCE MEASURES'. For further information on the above-mentioned and other non-GAAP financial measures used in this press relea se, see the Glossary in AXA's 2025 Activity Report. AXA's 2025 Activity Report is available on AXA's website (www.axa.com).

(3) AXA completed the disposal of AXA IM to BNP Paribas on July 1, 2025. All figures excluding AXA IM are given at constant foreign exchange rates.

(4) On July 1, 2025, AXA executed a share repurchase agreement with an investment services provider, whereby AXA carried out a program to buyback its own shares for a maximum amount of Euro 3.8 billion to offset the earnings dilution from the sale of AXA Investment Managers to BNP Paribas, as announced on August 1, 2024. The share buyback commenced on July 2, 2025, and ended on January 20, 2026, resulting in a temporary earnings dilution as of December 31, 2025.

(5) The Solvency II ratio is estimated primarily using AXA's internal model calibrated based on an adverse 1/200 years shock. For further information on AXA's internal model and Solvency II disclosures, please refer to AXA Group's Solvency and Financial Condition Report (SFCR) as of December 31, 2024, available on AXA's website (www.axa.com). The Solvency II ratio as of December 31, 2025 is adjusted to give effect to the full up to Euro 1.25 billion annual share buyback program and proposed Euro 2.32 per share dividend announced today.

(6) Capital instruments and subordinated debt subject to Solvency II transitional measures were grandfathered until January 1, 2026, at which point they ceased to qualify as capital under Solvency II, as disclosed in AXA's press release on its 9M25 Activity Indicators, published on www.axa.com.

(7) Subject to approval by the Shareholders' Annual General Meeting to be held on April 30, 2026.

(8) As approved by AXA's Board of Directors on February 25, 2026, and expected to commence as soon as reasonably practicable, subject to market conditions.

(9) Expected underlying earnings per share ('UEPS') growth for 2026 is a forward -looking statement to provide one-off guidance in the context of the last year of the Group's current strategic plan and is qualified by the cautionary statements in this press rel ease regarding forward-looking statements.

(10) Estimated based on the Solvency Capital Requirement (SCR) and the amount of capital under Solvency II as of January 1, 2026, as if the Solvency II revision had come into force on the same date.

(11) 'Commercial lines' refers to P&C Commercial lines excluding AXA XL Reinsurance.

(12) Price effects are calculated as a percentage of total gross written premiums of the prior year.

(13) General account.

(14) Including banking activities.

(15) Including P&C. Please see Appendices of the FY25 earnings presentation available at www.axa.com for indicative sensitivities impacting CSM. These sensitivities, together with any other sensitivities contained in the Appendices, are based on management's current assessment in connection with the full -year 2025 annual results. These sensitivities are expressly qualified by the cautionary statements in the presentation concerning forward looking statements and have not been audited or subject to a limited review by AXA's statutory auditors.

(16) Including cash and liquid invested assets at AXA SA Holding and other central holdings.

(17) To be executed in accordance with the terms of the Shareholders' Annual General Meeting authorization granted on April 2 4, 2025, or the authorization expected to be granted by the Shareholders' Annual General Meeting on April 30, 2026, as applicable.

(18) Natural catastrophe charges include natural catastrophe losses regardless of event size.

(19) Subject to annual Board and Shareholders' Annual General Meeting approvals and absent (1) for share buybacks, any significant earnings event (i.e., significant deviation in the Group's underlying earnings) and (2) for dividends, the occurrence of a signifi cant capital event (i.e., event that significantly deteriorates Group solvency). Board discretion includes taking into account AXA's earnings, financial condition, applicable c apital and solvency requirements, prevailing operating and financial market conditions and the general economic environment.

(20) Payout ratio is calculated based on underlying earnings per share.

(21) Life & Health net flows, PVEP, CSM, NB CSM, NBV, and NBV margin include Health business predominantly written in Life entities.

(22) Restricted Tier 1: 'BBB+' by Standard & Poor's and 'Baa1(hyb)' by Moody's. Tier 2: 'A -/Stable' by Standard & Poor's and 'A2(hyb)/Stable' by Moody's.

(23) AXA completed its acquisition of a majority stake in Prima in Italy on November 28, 2025.

(24) Disposal to BNP Paribas completed on July 1, 2025.

c. 39; p. 11 Basis of preparation and financial statement approval

• All comments and changes for activity indicators are on a comparable basis (constant forex, scope, and methodology).
• Actuarial and financial assumptions for NBV and PVEP calculations are updated semi-annually at half-year and full-year.
• AXA's consolidated financial statements for the year ended December 31, 2025, were examined by the Board of Directors on February 25, 2026.
• The financial statements are subject to completion of an audit procedure by AXA's statutory auditors.

c. 40; p. 12 Company information and cautionary statements

• AXA Group has 156,000 employees serving over 92 million clients in 52 countries.
• In 2025, IFRS17 revenues were Euro 115.5 billion.
• In 2025, IFRS17 underlying earnings were Euro 8.4 billion.
• Investor Relations contact: +33.1.40.75.48.42, investor.relations@axa.com.
• The AXA ordinary share is listed on compartment A of Euronext Paris under ticker symbol CS (ISN FR 0000120628 – Bloomberg: CS FP – Reuters: AXAF.PA).
• AXA’s American Depository Share is quoted on the OTC QX platform under ticker symbol AXAHY.
• Individual Shareholder Relations contact: +33.1.40.75.48.43.
• Media Relations contacts: +33.1.40.75.46.74, ziad.gebran@axa.com, ahlem.girard@axa.com, sylwia.tulak@axa.com.
• The AXA Group is included in international SRI indexes like Dow Jones Sustainability Index (DJSI) and FTSE4GOOD.
• AXA is a founding member of the UN Environment Programme’s Finance Initiative (UNEP FI) Principles for Sustainable Insurance and a signatory of the UN Principles for Responsible Investment.
• Forward-looking statements in the press release, including those regarding expected underlying earnings per share (UEPS) growth for 2026, are based on Management’s current views and intentions and are subject to change.
• Undue reliance should not be placed on forward-looking statements due to known and unknown risks and uncertainties outside AXA’s control.
• AXA disclaims any obligation to publicly update or revise forward-looking statements, except as required by applicable laws and regulations.
• The press release refers to non-GAAP financial measures (APMs) used by Management, which may not be comparable to measures used by other companies.
• Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, the Group’s consolidated financial statements prepared in accordance with IFRS.
• "Underlying earnings", UEPS, "underlying return on equity", "combined ratio", and "debt gearing" are APMs as defined in ESMA’s guidelines and the AMF’s related position statement.
• Reconciliations of APMs to IFRS financial statements and their calculation methodology are provided in AXA’s 2025 Activity Report.

Appendix 1: Gross written premiums et other revenues by geography and business line

c. 41; p. 13

10 | Gross Written Premiums and Other revenues by geography and business line, FY24 vs FY25.

In EUR million	Gross Written Premiums and Other Revenues FY24	Gross Written Premiums and Other Revenues FY25	Gross Written Premiums and Other Revenues Change on a reported basis	Gross Written Premiums and Other Revenues Change on a comparable basis	o/w Property & Casualty FY25	o/w Property & Casualty Change on a comparable basis	o/w Life & Health FY25	o/w Life & Health Change on a comparable basis	o/w Asset Management FY25	o/w Asset Management Change on a comparable basis
Francei(footnote: Including Banking revenues amounting to Euro 99 million in FY25 and Euro 118 million in FY24.)	28,996	30,598	+6%	+6%	9,648	+7%	20,852	+5%	—	—
Europe	39,298	43,005	+9%	+6%	21,257	+4%	21,748	+8%	—	—
AXA XL	19,383	19,277	-1%	+4%	19,159	+4%	118	-8%	—	—
Asia, Africa & EME-LATAM	19,083	19,925	+4%	+13%	6,257	+13%	13,668	+13%	—	—
Transversal	1,856	1,844	-1%	-1%	1,718	-1%	126	-8%	—	—
AXA Investment Managers	1,701	875	-49%	+4%	—	—	—	—	875	+4%
Totali(footnote: Including Banking revenues amounting to Euro 99 million in FY25 and Euro 118 million in FY24.)	110,316	115,524	+5%	+6%	58,038	+5%	56,512	+8%	875	+4%

(i) Including Banking revenues amounting to Euro 99 million in FY25 and Euro 118 million in FY24.

Appendix 2: Underlying earnings by geography and by business line

c. 42; p. 14

11 | Underlying earnings by geography and by business line, FY24 vs FY25.

In EUR million	Underlying earnings FY24	Underlying earnings FY25	Underlying earnings Change at constant Forex	o/w Property & Casualty FY25	o/w Property & Casualty Change at constant Forex	o/w Life & Health FY25	o/w Life & Health Change at constant Forex	o/w Asset Management FY25	o/w Asset Management Change at constant Forex
France	2,071	2,224	+7%	1,237	+7%	1,039	+8%	—	—
Europe	3,187	3,486	+9%	2,216	+9%	1,264	+14%	—	—
AXA XL	1,820	1,893	+9%	1,913	+9%	12	-49%	—	—
Asia, Africa & EME-LATAM	1,504	1,493	+6%	355	+24%	1,165	0%	—	—
Transversal	-907	-903	0%	151	-4%	22	+16%	—	—
AXA Investment Managers	402	175	-57%	—	—	—	—	175	-57%
Totali(footnote: Including underlying earnings of Holdings and Banking.)	8,078	8,368	+6%	5,872	+9%	3,501	+7%	175	-57%

(i) Including underlying earnings of Holdings and Banking.

Appendix 3: Property & Casualty – gross written premiums & other revenues by business line and discount rates

c. 43; p. 15

12 | Property & Casualty gross written premiums & other revenues by business line and geography, FY25.

In EUR million	Commercial lines Total Commercial	Commercial lines Changei	Personal lines Personal Motor	Personal lines Changei	Personal lines Personal Non-Motor	Personal lines Changei	AXA XL Reinsurance Total Personal	AXA XL Reinsurance Changei	AXA XL Reinsurance Total Reinsurance	AXA XL Reinsurance Changei	Total P&C FY25	Total P&C Changei
France	5,077	+6%	2,693	+9%	1,877	+10%	4,570	+9%	-	-	9,648	+7%
Europe	9,179	+1%	7,434	+6%	4,644	+5%	12,078	+5%	-	-	21,257	+4%
AXA XL	16,604	+3%	-	-	-	-	-	-	2,555	+8%	19,159	+4%
Asia, Africa & EME-LATAM	3,193	+13%	2,315	+14%	749	+12%	3,064	+14%	-	-	6,257	+13%
Transversal	1,718	-1%	-	-	-	-	-	-	-	-	1,718	-1%
Total	35,771	+4%	12,443	+8%	7,269	+7%	19,712	+7%	2,555	+8%	58,038	+5%

(i) Changes are at comparable basis (constant forex, scope and methodology)

13 | Property & Casualty: Interest rates (5Y) for the Discounting of P&C Claims Reserves by currency, FY24 vs FY25.

	FY24i	FY25ii(footnote: Average of monthly opening discount rates of 2025)
EUR	2.8%	2.6%
USD	4.4%	4.2%
JPY	0.4%	1.0%
GBP	4.3%	4.3%
CHF	0.8%	0.2%
HKD	3.7%	3.2%

(i) Calculated as monthly average from January 2024 to December 2024

(ii) Average of monthly opening discount rates of 2025

Appendix 4: Property & Casualty – price effect & 2026 market pricing trends

P&C: Price effects i by country and business line

c. 44; p. 16

14 | P&C: price effects by country and business line, FY25 with 2026 Market pricing trends.

FY25 (in %)	Commercial lines	Personal lines	AXA XL Reinsurance	2026 Market pricing trends
France	+4.0%	+3.3%	—	Moderation of price increase
Europe	+3.1%	+5.4%	—	—
Switzerland	+3.0%	+5.0%	—	Continued price increases both in Personal and Commercial lines
Germany	+3.1%	+10.3%	—	Moderation of price increase, notably in Personal lines following two years of high price increases to counter claims inflation
Belgium & Luxembourg	+2.5%	+4.4%	—	Price increase broadly in line with 2025
UK & Ireland	+1.4%	-2.6%	—	In UK Personal lines, continuation of current trend, continued moderation in Commercial lines
Spain	+8.8%	+8.6%	—	Moderation of price increase
Italy	+5.2%	+5.3%	—	Moderation of price increase
AXA XLii(footnote: ii. Price increase on renewals at +0.3% in Insurance and +0.2% in Reinsurance. Price increase on renewals calculated as a percentage of renewed premiums.)	+0.2%	—	+0.3%	Softening prices with conditions varying by lines
Asia, Africa & EME-LATAM	+3.8%	+7.1%	—	Moderation of price increase
Total	+1.9%	+5.2%	+0.3%	—

(i) i. Price effect calculated as a percentage of total gross written premiums in the prior year.

(ii) ii. Price increase on renewals at +0.3% in Insurance and +0.2% in Reinsurance. Price increase on renewals calculated as a percentage of renewed premiums.

Appendix 5: Life & Health – gross written premiums & other revenues and growth by business line

c. 45; p. 17

15 | Life & Health gross written premiums & other revenues and growth by business line, FY25.

Gross written premiums & other revenues In EUR million	Total FY25	Total Changei(footnote: Changes are at comparable basis (constant forex, scope and methodology))	o/w Protection FY25	o/w Protection Changei(footnote: Changes are at comparable basis (constant forex, scope and methodology))	o/w G/A Savings FY25	o/w G/A Savings Changei(footnote: Changes are at comparable basis (constant forex, scope and methodology))	o/w Unit-Linked FY25	o/w Unit-Linked Changei(footnote: Changes are at comparable basis (constant forex, scope and methodology))	o/w Health FY25	o/w Health Changei(footnote: Changes are at comparable basis (constant forex, scope and methodology))
France	20,852	+5%	4,650	+6%	5,483	+4%	5,109	+10%	5,611	+2%
Europe	21,748	+8%	5,090	+4%	4,444	+18%	3,419	+10%	8,795	+4%
AXA XL	118	-8%	59	-6%	59	-10%	-	-	-	-
Asia, Africa & EME-LATAM	13,668	+13%	7,454	+19%	971	-31%	761	+63%	4,483	+11%
Transversal	126	-8%	-	-	-	-	-	-	126	-8%
Total	56,512	+8%	17,253	+11%	10,957	+4%	9,289	+13%	19,014	+5%
o/w short-termii(footnote: Short-term business refers to insurance activities measured using the Premium Allocation Approach ('PAA'). Short-term business margin is analyzed using the Combined Ratio. Short-term business refers here to Life Pure Protection and Health when measured using the PAA period)	17,651	+6%	4,337	+6%	—	—	—	—	13,314	+6%

(i) Changes are at comparable basis (constant forex, scope and methodology)

(ii) Short-term business refers to insurance activities measured using the Premium Allocation Approach ('PAA'). Short-term business margin is analyzed using the Combined Ratio. Short-term business refers here to Life Pure Protection and Health when measured using the PAA period

Appendix 6: New business volume (PVEP), new business value (NBV), and NBV margin

c. 46; p. 18

16 | New Business Metrics: PVEP, NBV, and NBV margin by geography and business line, FY25.

Life New Business Metrics FY25 In EUR million	Life New Business Metrics FY25 PVEP	Life New Business Metrics FY25 Changeii(footnote: Changes are at comparable basis (constant forex, scope and methodology))	Life New Business Metrics FY25 NBV	Life New Business Metrics FY25 Changeii(footnote: Changes are at comparable basis (constant forex, scope and methodology))	Life New Business Metrics FY25 NBV margin	Life New Business Metrics FY25 Changeii(footnote: Changes are at comparable basis (constant forex, scope and methodology))	Healthi(footnote: Includes Health business written predominantly in Life entities) New Business Metrics FY25 PVEP	Healthi(footnote: Includes Health business written predominantly in Life entities) New Business Metrics FY25 Changeii(footnote: Changes are at comparable basis (constant forex, scope and methodology))	Healthi(footnote: Includes Health business written predominantly in Life entities) New Business Metrics FY25 NBV	Healthi(footnote: Includes Health business written predominantly in Life entities) New Business Metrics FY25 Changeii(footnote: Changes are at comparable basis (constant forex, scope and methodology))	Healthi(footnote: Includes Health business written predominantly in Life entities) New Business Metrics FY25 NBV margin	Healthi(footnote: Includes Health business written predominantly in Life entities) New Business Metrics FY25 Changeii(footnote: Changes are at comparable basis (constant forex, scope and methodology))	Totalii(footnote: Changes are at comparable basis (constant forex, scope and methodology)) New Business Metrics FY25 PVEP	Totalii(footnote: Changes are at comparable basis (constant forex, scope and methodology)) New Business Metrics FY25 Changeii(footnote: Changes are at comparable basis (constant forex, scope and methodology))	Totalii(footnote: Changes are at comparable basis (constant forex, scope and methodology)) New Business Metrics FY25 NBV	Totalii(footnote: Changes are at comparable basis (constant forex, scope and methodology)) New Business Metrics FY25 Changeii(footnote: Changes are at comparable basis (constant forex, scope and methodology))	Totalii(footnote: Changes are at comparable basis (constant forex, scope and methodology)) New Business Metrics FY25 NBV margin	Totalii(footnote: Changes are at comparable basis (constant forex, scope and methodology)) New Business Metrics FY25 Changeii(footnote: Changes are at comparable basis (constant forex, scope and methodology))
France	14,971	-4%	519	0%	3.5%	+0.1 pt	7,887	-20%	177	+13%	2.2%	+0.7pt	22,858	-10%	695	+3%	3.0%	+0.4pts
Europe	10,102	+3%	474	-11%	4.7%	-0.7pt	2,549	+16%	104	+36%	4.1%	+0.6pt	12,651	+5%	578	-5%	4.6%	-0.5pts
Asia, Africa & EME-LATAM	12,029	+7%	754	+5%	6.3%	-0.1pt	1,817	-6%	205	-12%	11.3%	-0.8pt	13,847	+5%	959	+1%	6.9%	-0.3pts
Total	37,103	+1%	1,747	-1%	4.7%	-0.1pt	12,254	-12%	486	+4%	4.0%	+0.6pt	49,357	-2%	2,233	0%	4.5%	+0.1pt

17 | NB CSM to NBV by business line, FY25.

NB CSM to NBV
In EUR million	Life	Healthi(footnote: Includes Health business written predominantly in Life entities)	Totali(footnote: Includes Health business written predominantly in Life entities)
NB CSM (pre-tax)	1,822	377	2,199
Other NBV (pre-tax)	491	266	757
Tax & Other	-567	-157	-724
NBV	1,747	486	2,233

(i) Includes Health business written predominantly in Life entities

(ii) Changes are at comparable basis (constant forex, scope and methodology)

Appendix 7: Life & Health – net flows

c. 47; p. 19

18 | Life & Health net flows by business line, FY24 vs FY25.

In EUR billion	FY24	FY25
Healthi(footnote: Includes Health business written predominantly in Life entities)	+2.7	+2.7
Protection	+3.2	+4.9
G/A Savings	-3.6	-3.7
o/w capital lightii(footnote: Capital light G/A encompasses all products with no guarantees, with guarantees at maturity only or with guarantees equal to or lower than 0%)	+2.2	+1.2
o/w traditional G/A	-5.8	-5.0
Unit-Linkediii(footnote: Including Investment contracts with no discretionary participation features ("DPF"))	-0.8	+1.5
Mutual Funds & Other	0.0	0.0
Total Life & Healthi(footnote: Includes Health business written predominantly in Life entities) net flows	+1.5	+5.4

(i) Includes Health business written predominantly in Life entities

(ii) Capital light G/A encompasses all products with no guarantees, with guarantees at maturity only or with guarantees equal to or lower than 0%

(iii) Including Investment contracts with no discretionary participation features ("DPF")

Appendix 8: Main transactions and next main investor events

c. 48; p. 20 Main transactions in 2025

• Announced the execution of a share repurchase agreement for AXA's share buyback program of up to EUR 1.2bn (February 28, 2025)
• Announced the completion of the acquisition of Nobis Group in Italy (April 1, 2025)
• Announced the placement of EUR 1bn Restricted Tier 1 Notes and EUR 1bn Tier 2 Notes (May 28, 2025)
• Announced the execution of a share repurchase agreement for AXA's Shareplan and certain stock-based compensation (June 2, 2025)
• Announced the completion of the sale of AXA Investment Managers to BNP Paribas (July 1, 2025)
• Announced the execution of a share repurchase agreement of up to EUR 3.8bn following the sale of AXA IM (July 1, 2025)
• Announced the acquisition of Prima, a direct insurance player in Italy (August 1, 2025)
• Announced the launch (September 10, 2025) and successful completion (December 3, 2025) of the 2025 employee share offering program (Shareplan 2025)
• Announced the placement of EUR 750m Restricted Tier 1 Notes and EUR 750m Tier 2 Notes (October 14, 2025)
• Announced the completion of the acquisition of a majority stake in Prima in Italy (November 28, 2025)

Next main investor events

c. 49; p. 20 Investor events 2026

• 2026 Shareholder's Annual General Meeting: April 30, 2026
• First quarter 2026 Activity Indicators: May 5, 2026
• HY26 Earnings Release: July 31, 2026
• AXA Investor Day: September 21, 2026